Post-earnings recap
Reported
Thu, Mar 7, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Corcept Therapeutics reported a loss per share that was slightly worse than expected, but the stock still rose by 2.19%. This increase may reflect investor confidence in the company's long-term potential, particularly regarding its product pipeline. The lack of revenue figures and guidance leaves some uncertainty, but management's focus on R&D could be a positive sign for future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | -5.88% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about future growth. They highlighted their focus on advancing their product pipeline.
Management emphasized ongoing commitment to research and development.
They noted the importance of upcoming product pipeline developments.
Est. EPS
—
Est. Rev
—
Impl. Move
—